NICE changes its mind on rare bile duct cancer drug from IncyteIncyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, Share XNICE changes its mind on rare bile duct cancer drug from Incytehttps://pharmaphorum.com/news/nice-changes-its-mind-on-rare-bile-duct-cancer-drug-from-incyte/
NICE’s second Zytiga rejection ‘shows need for flexible pricing models’NICE has stuck with its original decision to reject NHS funding for Johnson & Johnson’s Zytiga as a Share XNICE’s second Zytiga rejection ‘shows need for flexible pricing models’https://pharmaphorum.com/news/nice-second-zytiga-rejection-shows-need-for-flexible-pricing-models/
NICE feedback?The National Institute for Health and Care Excellence (NICE) is quite far along a NICE-led process to review Share XNICE feedback?https://pharmaphorum.com/views-and-analysis/nice-feedback/
NICE rejects Orchard’s gene therapy for rare childhood disease MLDOrchard Therapeutics’ gene therapy for rare childhood disease metachromatic leukodystrophy (MLD) Libmeldy has been rejected for NHS use Share XNICE rejects Orchard’s gene therapy for rare childhood disease MLDhttps://pharmaphorum.com/news/nice-rejects-orchards-gene-therapy-for-rare-childhood-disease-mld/
MHRA grants bluebird ‘innovation passport’ for sickle cell therapybluebird bio’s sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an ‘innovation passport’ introduced Share XMHRA grants bluebird ‘innovation passport’ for sickle cell therapyhttps://pharmaphorum.com/news/mhra-grants-bluebird-innovation-passport-for-sickle-cell-therapy/
NICE backs Novartis’ Cosentyx for underdiagnosed back conditionNICE has extended the range of indications that Novartis’ Cosentyx can be prescribed for by the NHS in Share XNICE backs Novartis’ Cosentyx for underdiagnosed back conditionhttps://pharmaphorum.com/news/nice-backs-novartis-cosentyx-for-underdiagnosed-back-condition/
Artificial pancreas will be piloted in 1,000 diabetics, says NHS CEONHS England will provide artificial pancreas devices to 1,000 type 1 diabetes patients as part of a pilot Share XArtificial pancreas will be piloted in 1,000 diabetics, says NHS CEOhttps://pharmaphorum.com/news/artificial-pancreas-will-be-piloted-in-1000-diabetics-says-nhs-ceo/
How the patient voice is becoming vital for drug approvalRebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed Share XHow the patient voice is becoming vital for drug approvalhttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/patient-voice-drug-approvals-lipodystrophy/
Time for a NICE changeThe National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and Share XTime for a NICE changehttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/time-for-a-nice-change/
